Literature DB >> 9623437

Effect of continuous spinal remifentanil infusion on behaviour and spinal glutamate release evoked by subcutaneous formalin in the rat.

H Buerkle1, M Marsala, T L Yaksh.   

Abstract

Injection of formalin into the hind paw of the rat evokes a biphasic nociceptive behavioural response, which is considered to be an animal model of postoperative pain in humans. The initial response (phase 1) is caused by activation of peripheral nociceptors and is followed by a second phase attributed to ongoing activity in primary afferents and increased sensitivity of dorsal horn neurones. The latter effect is thought to result from glutamate-mediated N-methyl-D-aspartate receptor activation. In studies to date it has been difficult to discriminate mechanisms underlying phase 1 and phase 2 events because of the long-lasting half-times of intrathecally administered opioids. To further understanding of the opioid pharmacology of the two different phases of the formalin test, we have studied behavioural activity and spinal glutamate release after intrathecal administration of remifentanil, a new short-lasting mu opioid. Intrathecal remifentanil 3 micrograms microliter-1 min-1 delivered during phase 1 inhibited behavioural response during phase 1 (100%), but did not abolish subsequent phase 2 behavioural activity completely (67 (12) %). Intrathecal remifentanil administered separately in phase 1 and phase 2 revealed a similar ED50 (0.2 microgram microliter-1 min-1) for inhibition of the behavioural responses. In vivo, spinal microdialysis showed incomplete reduction in glutamate concentrations in response to intrathecal remifentanil administration; this in turn inhibited phase 1 behavioural responses. Therefore we contend that supramaximal doses of intrathecal remifentanil sufficient to inhibit phase 1 activity still permitted sufficient glutamate release to allow spinal facilitation. Incomplete suppression of spinal excitatory neurotransmitter release by intrathecal opioids is consistent with spinal wind-up that is triggered during phase 1 and results in phase 2 afferent drive. This might reflect one of the mechanisms underlying post-operative pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623437     DOI: 10.1093/bja/80.3.348

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

Review 1.  The spinal biology in humans and animals of pain states generated by persistent small afferent input.

Authors:  T L Yaksh; X Y Hua; I Kalcheva; N Nozaki-Taguchi; M Marsala
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 2.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

3.  Effects of general anesthetics on substance P release and c-Fos expression in the spinal dorsal horn.

Authors:  Toshifumi Takasusuki; Shigeki Yamaguchi; Shinsuke Hamaguchi; Tony L Yaksh
Journal:  Anesthesiology       Date:  2013-08       Impact factor: 7.892

4.  Systemic and spinal administration of the mu opioid, remifentanil, produces antinociception in amphibians.

Authors:  Shekher Mohan; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2006-02-17       Impact factor: 4.432

5.  Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state.

Authors:  Sarah A Woller; Satheesh B Ravula; Fabio C Tucci; Graham Beaton; Maripat Corr; R Rivkah Isseroff; Athena M Soulika; Marianne Chigbrow; Kelly A Eddinger; Tony L Yaksh
Journal:  Brain Behav Immun       Date:  2016-04-01       Impact factor: 7.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.